Globally, lung cancer is responsible for around 1.8 million deaths every year. Credit: kalhh / Pixabay.

Median Technologies has reported positive performance for its iBiopsy artificial intelligence (AI)-powered Computer-Aided Diagnosis (CADx) product for lung cancer screening (LCS) to characterise malignant and benign lung nodules.

The assessment follows a large-scale study that included a cohort of 1,696 patient cases from the National Lung Screening Trial (NLST) with a total of 15,608 lung nodules.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The training set was based on 1,224 patients, while the test set was based on 472 patients.

iBiopsy CADx demonstrated 95.2% sensitivity and 95.7% specificity for lung nodule characterisation, displaying an AUC of 0.991.

Median founder and CEO Fredrik Brag said: “We have achieved an outstanding performance with our innovative deep learning algorithm for lung nodule characterisation.

“This promising and powerful digital biomarker could have a profound impact on lung cancer screening and help to dramatically reduce the 1.8m lung cancer deaths per year by diagnosing lung cancer patients at a stage that could save their lives.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Our plan in the coming months is to perform an additional large-scale study for an end-to-end lung cancer screening digital biomarker. Results of this study including both nodule detection (CADe) and characterisation in Q4, 2021.”

Several studies have shown that low-dose computed tomography (LDCT) LCS can reduce mortality rates among patients significantly.

However, screening efforts suffer from low rates of adoption primarily due to the challenges in characterising malignant from benign nodules.

Median Technologies expects that iBiopsy CADx can help in eliminating barriers and support widespread LCS adoption.

Earlier this year, Median signed a research collaboration agreement with the University of California San Diego, in the US, regarding iBiopsy.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact